期刊
CELL STEM CELL
卷 10, 期 6, 页码 740-749出版社
CELL PRESS
DOI: 10.1016/j.stem.2012.05.010
关键词
-
资金
- NIH [R24DK092760, UO1-HL100001, RC4-DK090913, P50HG005550]
- ARRA [RC2-HL102815]
- Roche Foundation for Anemia Research
- Alex's Lemonade Stand
- Ellison Medical Foundation
- Doris Duke Medical Foundation
- Harvard Stem Cell Institute
Stem cells are the seeds of tissue repair and regeneration and a promising source for novel therapies. However, apart from hematopoietic stem cell (HSC) transplantation, essentially all other stem cell treatments remain experimental. High hopes have inspired numerous clinical trials, but it has been difficult to obtain unequivocal evidence for robust clinical benefit. In recent years, unproven therapies have been widely practiced outside the standard clinical trial network, threatening the cause of legitimate clinical investigation. Numerous challenges and technical barriers must be overcome before novel stem cell therapies can achieve meaningful clinical impact.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据